According to an announcement, the vaccine co-developed by Pfizer and BioNTech is 90% effective in preventing Covid-19 infection in ongoing Phase 3 trials. In addition, the announcement was made as the Covid-19 case soared around the world, and European stock markets and oil prices recorded an increase.
Based on the initial findings, the level of protection for patients was successfully achieved for a period of 7 days after receiving the second injection after 28 days of obtaining the first injection.
Pfizer chief and CEO Albert Bourla stated that the first results of their Phovid-19 Phase 3 vaccine test have proven that the vaccine is capable of preventing the outbreak.
In addition, supply projections indicate that the companies say they will provide up to 50 million doses of vaccine worldwide by 2020, and up to 1.3 million doses by 2021.
In addition, US biotechnology firm Moderna and several government-run Chinese laboratories, and European projects led by the University of Oxford and AstraZeneca are alleged to be developing potential vaccines.
In addition, 2 Russian Covid-19 vaccines were registered before clinical trials were completed, but have not been widely accepted outside Russia.
Meanwhile, the Level 3 clinical trial test, the final stage for the new vaccine, BNT162b2, started at the end of July and has registered a total of 43,538 participants to date with 90% of them receiving the second dose of vaccine candidates on November 8.
Pfizer says they are collecting safety data for 2 months after the last dose and it is a condition imposed by the U.S. Food and Drug Administration to obtain Emergency Consumption Permits, which it expects in the third week of November.
